Non-viral Causes of Liver Enzymes Elevation in Post Renal Transplant Patients
DOI:
https://doi.org/10.70749/ijbr.v3i6.1796Keywords:
Liver Enzymes Elevation, Post Renal Transplant, Incidence of LEE, Kidney Transplant Recipients, Liver EnzymeAbstract
Background: Following kidney transplantation, liver enzyme elevations (LEE) are often observed and can result from a number of causes, such as immunosuppressive medications, viral infections, and other underlying illnesses. Objectives: The aim of this study was to ascertain the incidence of LEE and identify the risk factors related to it. Patients and Methods: 200 KTRs who had received a transplant and were clear of HBV and HCV infections were included in the study. In kidney transplant recipients (KTRs) who tested negative for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibodies (HCV Ab) and were free of other liver illnesses. Between December 2022 and May 2023, 200 kidney transplant patients (113 men and 87 women) participated in this observational perspective analysis. All recipients had their liver enzyme levels and other biochemical markers, such as complete blood counts, cyclosporine levels, and serum creatinine, assessed. Based on the amount of time that had passed following the transplant, the participants were split into three groups: Group I (less than three months), Group II (4–12 months), and Group III (more than a year post-transplant). Results: Incidence of LEE was greatest in male recipients (P < 0.001) and older individuals (P < 0.001). Patients who received kidneys from deceased donors were more likely to have elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) than those who received kidneys from living donors (10.4% vs. 5.6% for AST and 23.8% vs. 14.8% for ALT, respectively, P < 0.001). ALT had the greatest incidence of increase among the liver enzymes, occurring in 34.3% of patients. Following transplantation, ALT and AST levels were considerably higher in the first three months and decreased in the fourth to twelve months (P < 0.001). Both univariate and linear regression studies showed a negative relationship between liver enzyme levels and renal allograft function, which grew stronger over time. Furthermore, it was shown that, although this association waned with time, cyclosporine blood levels were strongly correlated with abnormal liver enzymes. Additionally, there was a correlation between LEE and these individuals' anemia. Conclusion: In kidney transplant recipients, especially in the early post-transplant phase, liver enzyme increases are a frequent and noteworthy observation. All kidney transplant recipients should have their aminotransferases, particularly ALT, regularly and serially monitored in order to identify liver malfunction early and treat any problems.
Downloads
References
1. Agarwal, S. K. (2010). Hepatitis B infection during renal replacement therapy. Hepatitis Monthly, 10(4), 255.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3271317/
2. Du, L., & Tang, H. (2011). Treatment of HCV patients before and after renal transplantation. Hepatitis Monthly, 11(11), 880-886.
https://doi.org/10.5812/kowsar.1735143x.3747
3. Rostami, Z., Nourbala, M. H., Alavian, S. M., Bieraghdar, F., Jahani, Y., & Einollahi, B. (2011). The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepatitis Monthly, 11(4), 247.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3206701/
4. Einollahi, B. (2012). Therapy for HBV infection in hemodialysis patients: Is it possible? Hepatitis Monthly, 12(3), 153-157.
https://doi.org/10.5812/hepatmon.834
5. Mahdavi-Mazdeh, M. (2011). Controlling HCV infection in hemodialysis units. Nephro-Urology Monthly, 3(4), 311-312.
https://brieflands.com/articles/num-71615.pdf
6. Salinitri, F. D., Hsaiky, L., & Pinelli, N. R. (2011). Hepatitis C Virus Infection Complicated by Kidney Disease. Nephro-Urol Mon, 3(4), 308-310.
7. Zahedi, M. J., Moghaddam, S. D., Alavian, S. M., & Dalili, M. (2012). Seroprevalence of hepatitis viruses B, C, D and HIV infection among hemodialysis patients in Kerman province, south-east Iran. Hepatitis Monthly, 12(5), 339-343.
https://doi.org/10.5812/hepatmon.5969
8. Alavian, S. M., Einolahi, B., Sadeghi-Gahroodi, M., & Hosseini, S. M. (2002). Liver enzymes level evaluation in renal tranplanted group. Modarres J Med Sci, 5(1), 87-92.
9. Gutkowski, K., Chwist, A., & Hartleb, M. (2011). Liver injury induced by high-dose Methylprednisolone therapy: A case report and brief review of the literature. Hepatitis Monthly, 11(8), 656-661.
https://doi.org/10.5812/kowsar.1735143x.713
10. Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002). Mechanisms of clinically relevant drug interactions associated with Tacrolimus. Clinical Pharmacokinetics, 41(11), 813-851.
https://doi.org/10.2165/00003088-200241110-00003
11. Espinosa, M., Martin-Malo, A., Alvarez de Lara, M. A., Soriano, S., & Aljama, P. (2000). High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clinical nephrology, 54(2), 151-156.
https://europepmc.org/article/med/10968693
12. Aronoff, A., Gault, M. H., Huang, S. N., Lal, S., Wu, K. T., Moinuddin, M. D., ... & MacLean, L. D. (1973). Hepatitis with Australia antigenemia following renal transplantation. Canadian Medical Association Journal, 108(1), 43.
https://pmc.ncbi.nlm.nih.gov/articles/PMC1941116/
13. Berne, T. V., SN, C., & JE, P. (1975). HEPATIC DYSFUNTION IN RECIPIENTS OF RENAL ALLOGRAFTS. Surg Gynecol Obstet, 141(2), 171–5.
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=PASCAL7650042620
14. Ireland, P. (1973). Liver disease in kidney transplant patients receiving azathioprine. Archives of Internal Medicine, 132(1), 29.
https://doi.org/10.1001/archinte.1973.03650070021004
15. Moore, T. C., & Hume, D. M. (1969). The period and nature of hazard in clinical renal transplantation. Annals of Surgery, 170(1), 12-24.
https://doi.org/10.1097/00000658-196907000-00002
16. Debure, A., Legendre, C., Kreis, H., Degott, C., Carnot, F., Pol, S., & Brechot, C. (1990). Chronic hepatitis in kidney allograft recipients. The Lancet, 335(8694), 878-880.
https://doi.org/10.1016/0140-6736(90)90477-m
17. LAQUAGLIA, M. P., TOLKOFF-RUBIN, N. E., DIENSTAG, J. L., Cosimi, A. B., HERRIN, J. T., KELLY, M., & RUBIN, R. H. (1981). Impact of hepatitis on renal transplantation. Transplantation, 32(6), 504-507.
https://doi.org/10.1097/00007890-198112000-00011
18. London, W. T., Drew, J. S., Blumberg, B. S., Grossman, R. A., & Lyons, P. J. (1977). Association of Graft survival with host response to hepatitis B infection in patients with kidney transplants. New England Journal of Medicine, 296(5), 241-244.
https://doi.org/10.1056/nejm197702032960502
19. Malekzadeh, M. H., Grushkin, C. M., Wright, H. T., & Fine, R. N. (1972). Hepatic dysfunction after renal transplantation in children. The Journal of Pediatrics, 81(2), 279-285.
https://doi.org/10.1016/s0022-3476(72)80296-8
20. Moore, T. C., & Hume, D. M. (1969). The period and nature of hazard in clinical renal transplantation. Annals of Surgery, 170(1), 25-29.
https://doi.org/10.1097/00000658-196907000-00003
21. Reeve, C. E., Martin, D. C., Gonick, H. C., Kaufman, J. J., Rubini, M. E., Mimms, M. M., ... & Goldman, R. (1969). Kidney transplantation: A comparison of results using cadaver and related living donors. The American Journal of Medicine, 47(3), 410-420.
https://doi.org/10.1016/0002-9343(69)90225-3
22. Lorber, M. I., Flechner, S. M., Van Buren, C. T., Sorensen, K., Kerman, R. H., & Kahan, B. D. (1987). Cyclosporine toxicity: The effect of combined therapy using Cyclosporine, azathioprine, and prednisone. American Journal of Kidney Diseases, 9(6), 476-484.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research

This work is licensed under a Creative Commons Attribution 4.0 International License.